

30 Nov - 1 Dec
Loews Coronado Bay Resort, San Diego, USA

Integrating the technologies revolutionising immunotherapy and its impact on vaccines development

PART OF

CREATED BY

Introducing the world vaccine & immunotherapy congress

Following on from the highly successful World Vaccine Congress series in Washington DC and Europe for the past **18 years**, we're bringing the **World Vaccine & Immunotherapy Congress** to San Diego this year, taking place **Nov 30-Dec 1**. We're integrating the technologies revolutionising immunotherapy and its impact on vaccines development.

Driven by the scientific and strategic growth in both sectors, this San Diego congress will offer **cutting edge science** and **partnership** opportunities, taking advantage of the **rich biotech** and **funding** environment that the west coast offers. This is the congress for **top decision makers** of the vaccine and immunotherapy industry with both scientific

and commercial interests. No matter where your interest lies we have content, networking and potential partners for you.

With the launch of San Diego as the Research Hub for the **Human Vaccines Project** make sure you at the forefront of vaccine research by joining us with the Project during the congress sessions. We have also taken advantage of **San**

Francisco's cancer hub and incorporated hard hitting plenaries and dedicated session tracks on **new immuno-oncology approaches**.

How have we delivered such a unique combination? We thank our **Scientific Advisory Board members** for their contribution to the agenda this year:



Dr Biol. Sci. Alessandro Sette
Center Head, Division Head, and Professor Center for Infectious Disease
La Jolla Institute



Dr Peter Hotez
MD PhD, Professor and Director, **Texas Children's Hospital Center** for Vaccine Development, and Dean of the **National School of Tropical Medicine**, Baylor College of Medicine



Dr Jerald Sadoff
Senior Advisor
Janssen Infectious Diseases and Vaccines



Dr Roy Baynes
Senior Vice President Global Clinical Development and Chief Medical Officer
MSD



Dr Karin Jooss
Executive Vice President of Research, and Chief Scientific Officer
Gritstone



Dr Steven Reed
Founder, President, and CSO
Infectious Disease Research Institute (IDRI)



Prof Bali Pulendran
Professor in the Department of Pathology, and Microbiology & Immunology
Stanford University School of Medicine



Dr Wayne C. Koff
President and CEO - The Human Vaccines Project
International Aids Vaccine Initiative Inc

SPEAKERS



Sean Tucker
CSO and VP Research
Vaxart



Franco Pissani
Scientific Advisor, Marketing
& Business Development
Infectious Disease
MabTech



Kurt Kamrud
Senior Director, Viral Systems
Synthetic Genomics



Jessica Flechtner
CSO
Genocea Biosciences



Erza Cohen
Associate Director, Moores
Cancer Center
Professor of Medicine
UC San Diego Moores Cancer
Center



David Anderson
Chief Scientific Officer
VBI Vaccines



Terry Moore
Founder and Managing
Partner
Moore Venture Partners



Maria Karasarides
Sr. Director,
ImmunoOncology, Global
Medicines Development
AstraZeneca



Pedro Beltran
Executive Director, Oncology
Research
Amgen



Colin Havenar-Daughton
Scientific Associate
La Jolla Institute for Allergy
and Immunology



Dr Peter Hotez
MD PhD, Professor and
Director, Texas Children's
Hospital Center for
Vaccine Development,
and Dean of the National
School of Tropical
Medicine, Baylor College
of Medicine



Kara Bortone
Director of Venture Sourcing
& Development for JLABS
Jlabs



JoAnn Suzich
VP, Infectious Disease &
Vaccine Research
Medimmune



Audray Harris
Chief, Structural Informatics
Unit, Laboratory of Infectious
Diseases
NIH/NIAID



Steven Burakoff
Director, Tisch Cancer Institute,
Professor Oncological
Sciences, Professor Medicine,
Hematology and Medical
Oncology
Tisch Cancer Institute, Icahn
School of Medicine at Mount
Sinai



Steven Townson
Research Scientific Director
Western Region, Global
Center for Scientific Affairs
Merck



Robert Sinkovits
Director Scientific
Applications Group
San Diego Supercomputer
Center, UCSD



Ruchita Sinha
Senior Director of
Investments
Sanofi-Genzyme Bioventures



James (Jim) Crowe
Center Head, Division Head,
Director | Immunologist, NIH
Board-Certified Pediatric
Infectious Diseases Specialist
Vanderbilt Vaccine Center



Laure Aurelian
Professor of Pharmacology,
Microbiology and
Immunology Dpt
Stanford University



Sean Bennett
Director of Senior Clinical
Development and Medical
Affairs
PaxVax



Steven Reed
Founder, President, and CSO
Infectious Disease Research
Institute (IDRI)




Hanneke Schuitemaker
VP, Head Viral Vaccine
Discovery and Translational
Medicine
Janssen Vaccines and
Prevention B.V.



Warren A Kibbe
Director of the Center for
Biomedical Informatics and
Information Technology
(CBIIIT) at the NCI.
NCI, NIH



Jean-Marie Cuillerot
Chief Medical Officer
Agenus Inc



Paul Robbins
Senior Director, Translational
Oncology
Pfizer



Drew Hannaman
Vice President, Research and
Development
Ichor Medical Systems



Alessandro (Alex) Sette
Center Head, Division Head,
and Professor Center for
Infectious Disease
La Jolla Institute for Allergy
and Immunology



Roger Dansey
SVP & Therapeutic Area
Head, Oncology Late-Stage
Developmen
Merck



Michael Kalos
Chief Scientific Officer,
Cancer Immunobiology
Eli Lilly



Ali Fattom
Sr VP of Vaccines Research
and Development
Nanobio Corporation



Adil Daud
HS Clinical Professor,
Department of Medicine
(Hematology/Oncology),
UCSF; Director, Melanoma
Clinical Research
UCSF School of Medicine,
Helen Diller Family
Comprehensive Cancer
Center



Simon Gill
Managing Director
Needham & Company LLC



Rajeev Dadoo
Partner
SR One (GSK)



Jon Armstrong
CSO
Cofactor Genomics



Jerry Sadoff
Senior Advisor
Janssen Infectious Diseases
and Vaccines



Steven Nagler
Executive Director
Medpro Investors



Dennis Burton
Co-chair, Department
of Immunology and
Microbiology
Scripps Research Institute



Steve Thorne
Chief Scientific Officer
Western Oncolytics



Glynn Wilson
CEO
TapImmune - cancer



Wouter Meuleman
Director, Venture Investments
Illumina Ventures



John Lee
SVP, medical affairs for
pediatric, adolescent and
young adult oncology
NantKwest



Richard Scheuermann
Director of Informatics
J. Craig Venter Institute



Karin Jooss
Chief Scientific Officer
Gritstone Oncology



Bali Pulendran
Professor in the Department
of Pathology and Laboratory
Medicine
Stanford University School of
Medicine



Manish Sadarangani
Investigator, BC Children's
Hospital, Assistant Professor,
Department of Pediatrics,
University of British Columbia,
Director, Vaccine Evaluation
Center
BC Children's Hospital
Research Institute



Tao Long
Assistant Professor,
Bioinformatics and Structural
Biology Program
Sanford Burnham Prebys
Medical Discovery Institute



Iana Dimkova
Director Healthcare Investing
GE Ventures




Stuart Barich
Managing Director,
Healthcare Investment
Banking
Raymond James



Edward Cha
Associate Medical Director
Genentech

Agenda Overview



DAY 1 AGENDA

PLENARY SESSION			
08:30	Chair's opening remarks		
08:40	Status of US vaccine and immunotherapy research in 2017 and beyond - Drivers moving the immunotherapy sector forward and its potential - Hurdles in vaccines research and the consequence of antivaxxers in national immunity - What regulatory or policy changes could affect the science, technology and funding to this sector?  Dr Peter Hotez MD PhD Professor and Director, Texas Children's Hospital Center for Vaccine Development, and Dean of the National School of Tropical Medicine Baylor College of Medicine  Dr Dennis Burton Co-chair, Department of Immunology and Microbiology Scripps Research Institute  Dr Ezra Cohen Associate Director, Moores Cancer Center, Professor of Medicine UCSD		
09:20	Human Vaccine Project: How much of the immune response do we understand? Deciphering the human immunome for a better vaccine design - How have technological advances in next-generation DNA sequencing offered ways to probe the human immune system? - Results so far on the Human Immunome that could lead to acceleration of vaccine development - Working toward a complete catalogue of expressed human immune receptors - Challenges in interpreting the vast amount of data into meaningful information  Dr James Crowe Director, Vanderbilt Vaccine Center Immunologist NIH Board-Certified Pediatric Infectious Diseases Specialist, Professor, Pediatrics and Pathology, Microbiology and Immunology, Vanderbilt Vaccine Center		
09:45	What can we learn from vaccine development for infectious diseases that can be applied to cancer and vice versa? - Bridging infectious disease vaccines with cancer immunotherapy - Technologies that are applicable to both including RNA vaccines - How to stimulate both humoral and cell-mediated immunity that are likely paramount for successful cancer immunotherapeutics - Understanding infectious vaccine approaches and immunological responses to strengthen cancer immunotherapeutic strategies  Dr Steven Reed Founder, President, and CSO Infectious Disease Research Institute (IDRI)  Dr Michael Kalos Chief Scientific Officer, Cancer Immunobiology Eli Lilly		
10:25	NEW: <i>Speed networking - Break the ice with your peers!</i> Allowing conference delegates to meet each other for a short space of time and exchange business cards. A unique feature guaranteeing heightened networking for all participants		
10:40	Morning Networking Break		
	INFECTIOUS DISEASES	IMMUNOTHERAPY	
11:40	Chair's opening remarks Dr Jerald Sadoff, Senior Advisor, Janssen Infectious Diseases and Vaccines	Chair's opening remarks	Chair's opening remarks

DAY 1 AGENDA

	IMMUNE CHARACTERISATION TECHNIQUES	NEW IMMUNOTHERAPY TRENDS	INVESTMENT PERSPECTIVES
11:45	The Human Vaccine Project’s first clinical trial: Understanding the rules of lifelong immunological protection Dr Manish Sadarangani, Assistant Professor, Department of Pediatrics, University of British Columbia, Director, Vaccine Evaluation Center, BC Children’s Hospital Research Institute	Personalized cancer vaccines that target patients-specific mutations: Platforms amenable for neoantigen vaccination Dr Jessica Baker Flechtner, CSO, Genocea Biosciences, Inc	VC Panel: Choosing the correct investment. Funding opportunities and investment strategies Stephen M. Nagler, Executive Director, MedPro Investors LLC Terry Moore, Founder and Managing Partner, Moore Venture Partners Dr Wouter Meuleman, Director, Venture Investments, Illumina Ventures <i>Additional panelists TBC shortly</i>
12:15	Lymph node fine needle aspirates to reveal correlates for immunization-induced neutralizing antibodies Dr Colin Havenar-Daughton, Scientific Associate, La Jolla Institute for Allergy and Immunology	The identification of tumor-host interactions that propagate an anti-tumor immune response Dr Maria Karasarides, Senior Director, ImmunoOncology, Global Medical Affairs, AstraZeneca	Investment Banking Panel: Status of the US vaccine & immunotherapy market Simon Gill, Managing Director, Needham & Co. Stu Barich, Managing Director, Healthcare Investment Banking, Raymond James <i>Additional panelists TBC shortly</i>
12:30			
12:45	Preliminary analysis of early innate immune responses to Hep B vaccination using single cell RNA sequencing approaches Dr Richard Scheuermann, Director of Informatics, J. Craig Venter Institute	Insights into combination studies across various tumor types Dr Edward Cha, Associate Medical Director, Genentech	
	RESPIRATORY & EMERGING DISEASES		
1:00	Clinical results of a novel oral Norovirus vaccine Dr Sean Tucker, CSO, Vaxart		
1:15	Networking Lunch & Poster Session		
2:45	Immune profiling of T cell responses correlating with pertussis vaccine efficacy Dr Biol. Sci. Alessandro Sette, Center Head, Division Head, and Professor Center for Infectious Disease, La Jolla Institute for Allergy and Immunology	Advanced immune characterization using RNA enables biomarker discovery in limiting and diverse samples Jon Armstrong, CSO, Cofactor Genomics	Corporate Venture Panel: Unique investment strategies and investing in platform technologies Iana Dimkova, Director Healthcare Investing, GE Ventures Dr Rajeev Dadoo, Partner, SR One Ruchita Sinha, Senior Director of Investments, Sanofi-Genzyme Bioventures <i>Additional panelists TBC shortly</i>
3:15	PhIII RSV vaccine for Infants via maternal immunization	Next generation biomarkers for the era of precision cancer immunotherapy Dr Steven M. Townson, Principal Scientist Clinical Research Oncology Early Development, Translational Oncology Group, Merck & Co., Inc	
3.30	Nasal vaccination increases efficacy and confers cross-protection against infectious diseases		A Regulatory Perspective – Clinical Considerations for Novel Immunotherapies Dr Ke Liu, Chief, Oncology Branch, Center for Biologics Evaluation and Research, Food and Drug Administration

DAY 1 AGENDA

3:45	ELISpot and FluoroSpot in vaccine research, development, and evaluation Dr Franco Pissani, Scientific Advisor, Marketing & Business Development, Mabtech	Increasing the potency of DNA-based immunotherapies using PolyStart peptide expression system Dr Glynn Wilson, Chairman & CEO, TapImmune	
4.00	Optimized presentation of antigens using enveloped Virus Like Particles Dr David E. Anderson, Ph.D., Chief Scientific Officer, VBI Vaccines	Progress of immune checkpoint antibodies and cancer vaccines as immunotherapies Dr Jean-Marie Cuillerot, Chief Medical Officer, Agenus Inc.	The decade of vaccines: How close are we to achieving our goals by 2020?
4:15	Networking Break		
4:45	Is it time to start considering antibodies as an alternative to vaccines? Dr JoAnn Suzich, VP, Infectious Disease & Vaccine Research, Medimmune	Mechanisms of action of Talimogene Laherparepvec: From Bench to Bedside Dr Pedro Beltran, Executive Director Oncology Research, Amgen	NEW TRENDS DISRUPTING THE LIFE SCIENCE SECTOR
5.00		Delivering multiple immunotherapies in a single construct; what makes WO-12 unique amongst oncolytic virotherapies? Dr Steve Thorne, Chief Scientific Officer, Western Oncolytics	The application of machine learning methods to accelerate the development of vaccines and immunotherapies Dr Robert Sinkovits, Director Scientific Applications Group, San Diego Supercomputer Center, UCSD
5:15	Using 3D Cryo-electron microscopy technology to determine the structures of vaccine nanoparticles to enable better vaccine design Dr Audray Harris, Chief, Structural Informatics Unit, Laboratory of Infectious Diseases, NIH	The generation and modulation of immunogenic cell death using oncolytic viruses Prof Laure Aurelian, Professor of Pharmacology, Microbiology and Immunology Dpt, University of Maryland	Blue Marble Health: An Innovative Plan to Fight Diseases of the Poor Amid Wealth Dr Peter Hotez MD PhD, Professor and Director, Texas Children's Hospital Center for Vaccine Development, and Dean of the National School of Tropical Medicine, Baylor College of Medicine
5:45	Chair closing remarks of day one followed by drinks reception and Meet & Greet with key speakers		



DAY 2 AGENDA


PLENARY SESSION	
08:30	Chair's opening remarks
08:40	Precision oncology needs data sharing: Integrating genomic and clinical data to advance patient care and understanding patient outcomes Dr Steven Burakoff Director The Tisch Cancer Institute, Professor of Medicine Icahn School of Medicine at Mount Sinai Dr Warren Kibbe Acting Deputy Director National Cancer Institute, Director, Center for Bioinformatics & Information Technology NIH Dr Adil Daud Professor, Hematology/Oncology University of California, San Francisco; Director, Melanoma Clinical Research UCSF Helen Diller Family Comprehensive Cancer Center
09:20	How to effectively manipulate the microbiome to improve efficacy of vaccines and immunotherapy Prof Bali Pulendran Professor in the Department of Pathology, and Microbiology & Immunology Stanford University School of Medicine Dr Kara Bortone Director of Venture Sourcing & Development for JLABS Johnson & Johnson Innovation

DAY 2 AGENDA

	INFECTIOUS DISEASES	IMMUNOTHERAPY
2:10	Chair's opening remarks	Chair's opening remarks
	VACCINE TECHNOLOGY PLATFORMS & DELIVERY	CLINICAL ADVANCEMENTS IN CANCER AND AUTOIMMUNE DISEASES
2:15	Developing vaccines for viral infections: Addressing HIV and Zika vaccine development Dr Hanneke Schuitemaker , VP, Head Viral Vaccine Discovery and Translational Medicine, Janssen Vaccine and Prevention B.V.	Development of novel, personalized neoantigen immunotherapies Dr Karin Jooss , Chief Scientific Officer, Gritstone Oncology
2:45	Development of a correlate of protection for a live oral cholera vaccine Dr Sean Bennett MD , PhD, Sr. Director Clinical Development & Medical Affairs, PaxVax	Optimizing the therapeutic benefit of PD-1 blockade and broadening the potential of immunotherapy Dr Roger Dansey , SVP & Therapeutic Area Head, Oncology Late-Stage Development, Merck
3:15	The use of next generation self-amplifying RNA platform systems for vaccine development Kurt Kamrud , Senior Director, Viral Systems Synthetic Genomics	Progress of chimeric antigen receptor (CAR) T-cells as an immuno-oncology treatment
3:30	Networking Break	
4:00	Electroporation mediated DNA immunization: Clinical progress and technology development Dr Drew Hannaman , Vice President of R&D, Ichor Medical Systems	Combining innate cellular therapy and adaptive immune therapy approaches for treatment of recurrent cancer John Lee , Senior Vice President, Adult Medical Affairs, NantKwest
4:15	A clinical development plan to advance Group A Streptococcus Vaccines (GAS)	Announcing a new immuno-oncology clinical trials unit to re-engage the body's immune system to revolutionize the treatment of cancer
4:30	Addressing a major public health concern; updates vaccine development for C.difficile	Updates in Ph3 clinical trials for avelumab Dr Paul Robbins , Senior Director, Translational Oncology, Pfizer *Session Title TBC
4.45	Mucosal immunity is critical for a successful development of efficacious vaccines against respiratory and sexually transmitted diseases vaccines Dr Ali Fattom , Sr VP of Vaccine Research and Development, NanoBio Corporation	
5:00	Chair's Closing Remarks & End of Congress	


Interactive Roundtables

Covering a number of hot topics and delivered by patient groups, sponsors and leading solution providers, choose which roundtable discussion you would like to join, for 'off the beaten track' learning and information you can't find online. The session will last 60 minutes.



Who Attends

The 720+ Vaccine & Cancer attendees in our April 2017 D.C annual came from 75% end users, over 300 companies, 300 countries



Big Pharma And Biotechs Who Attended In 2017 Include:

AERAS Astellas Pharma Inc Bavarian Nordic Baxter Biological E. Limited Boehringer Ingelheim CEPI Ceva Animal Health Department of Health and Human Services Eli Lilly and Company Emergent BioSolutions EpiVax Inc FDA FluGen Inc Genocoe Biosciences GSK Vaccines Health Canada Icahn School of Medicine at Mount Sinai Immunomic Therapeutics Indian Immunologicals Ltd Inovio Institut Pasteur Janssen Infectious Diseases and Vaccines La Jolla Infectious Disease Institute Mayo Clinic and Foundation Medicago MedImmune Inc Merck & Co. Merial Mitsubishi Tanabe Pharma Corporation Moderna Therapeutics National Cancer Institute New Link Genetics NIAID - NIH Novavax PATH Pfizer Sabin Vaccine Institute Sanaria Sanofi Pasteur SutroVax, Inc Takeda Pharmaceuticals The Bill & Melinda Gates Foundation The Human Vaccines Project The Jenner Institute - University of Oxford Valneva Vaxart VBI Vaccines Inc Walter Reed Army Institute Of Research World Health Organisation Zoetis Yisheng Biopharma Bharat Biotech Scrum Institute GAVI UNICEF IAVI Human Vaccine Project CDC HHS Stanford University School of Medicine Scripps University

How our Sponsors & Exhibitors benefit

Over the course of the 2 day meeting in San Diego, all the sponsors and exhibitors will benefit from direct F2F access with over 250 vaccine focused delegates where in total there will be over 10 hours of networking sessions taking place.

Different levels of partner involvement and activities offer the following:

01 / THOUGHT LEADERSHIP PRESENTATIONS

Deliver your message as a thought leader on a chosen topic to an audience of senior vaccine & immunotherapy stakeholders.

02 / CASE STUDY PRESENTATIONS

Showcase one of your best customer case studies to establish awareness and viability to a room full of prospects.

03 / PANEL DISCUSSIONS

Join senior vaccine stakeholders on panel discussions.

04 / TECHNOLOGY SHOWCASE

If you are a biotech or platform technology company, take the opportunity to present and showcase your latest work in the relevant conference agenda.

05 / EXHIBITION STANDS

Take an exhibition stand to showcase your services, products and solutions to over 250 vaccine & immunotherapy industry decision makers.

06 / BRANDING

Promote your brand to over 250 senior vaccine & immunotherapy executives by taking up high impact exhibition and theatre branding at the show.

Your networking opportunities



Bianca Geldenhuys
Networking manager

NETWORKING MANAGER

If you come in as a high-level sponsor, leading up to the event you will be assigned your very own Networking Manager who will be at your beck and call to help you set up meetings in advance of your arrival to the event. Your meeting schedule will be based on your desired targets on the delegate list. On-site, the Networking Manager will facilitate your meetings in a designated area.

NETWORKING DRINKS RECEPTION

It's not always about the conference sessions. Our themed evening networking drinks reception at the close of day one will allow you to unwind with your peers and continue conversations in good company.

SCIENTIFIC POSTERS

Share previous unpublished research with leaders in the vaccine field within the dedicated Scientific Poster area. Taking place during the lunch on day one of the congress, the Poster Session will make it possible for you to answer questions and gain feedback.

NETWORKING LUNCHES

Our extended lunch periods in the exhibition hall will provide you with ample time to network between sessions. These lunch formats allow for more opportunities for casual conversations and introductions at your booth.

The Exhibiton

WORLD VACCINE & IMMUNOTHERAPY

CONGRESS
WEST COAST



Floorplan last updated on 22 June 2017

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

Sponsors & Exhibitors include



Benefits	Title	Platinum	Gold	Silver	Bronze	Exhibitor	Table Top	Biotech Showcase
Keynote Plenary Speaking Slot (Morning)	1							
Speaking Slot in relevant track	1	1	1					1
Host a Roundtable	1	1	1		1			
Speak on a Panel Session	1	1 or Chair		1 or Chair				
Chair Half Day	1	1 or Panel		1 or Panel				
Pre-arranged on site meetings	*	*	*	*				
Exhibition Booth	20ft x 16ft	20ft x 8ft	10ft x 8ft	10ft x 8ft	10ft x 8ft	10ft x 8ft	6ft x 6ft	
Delegate Passes	8	5	4	3	2	2	1	1

Reserve your place today

The earlier you book the more you'll save. It's really easy to book your place online. And our online calculator will ensure you take advantage of the best deal. Go to and book now on www.terrapinn.com/wvc-west-coast

Package	14 Jul 2017	11 aug 2017	08 sep 2017	29 sep 2017	20 oct 2017	10 nov 2017	Final Price
2 Day Standard Package	\$1745 SAVE \$750	\$1870 SAVE \$625	\$1995 SAVE \$500	\$2120 SAVE \$375	\$2245 SAVE \$250	\$2370 SAVE \$125	\$2495
2 Day Academic & Regulatory Package	\$875 SAVE \$375	\$935 SAVE \$315	\$1000 SAVE \$250	\$1060 SAVE \$190	\$1125 SAVE \$125	\$1185 SAVE \$65	\$1250

BOOK NOW
www.terrapinn.com/wvc-west-coast
Book online now or call +44 (0) 207 092 1210